Once-weekly insulin for Type 2

A once-weekly basal insulin is in development to help treat Type 2 diabetes. Researchers suggest that reducing the frequency of basal insulin injections might help treatment acceptance and adherence among people with the condition.

The insulin icodec, by Novo Nordisk, shows comparable efficacy and safety to once-daily insulin glargine U100 after a 26-week randomised phase 2 trial involving 247 participants who had not previously received long-term insulin treatment and whose Type 2 diabetes was inadequately controlled.

The results have been published in the New England Journal of Medicine.



Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags